Common use of Interim Research and Development Reports Clause in Contracts

Interim Research and Development Reports. The CRADA PIs should shall exchange information in writing every three (3) months during the course of this CRADA. This exchange of information may be accomplished through meeting minutes, detailed correspondence, circulation of draft manuscripts, Steering Committee reports, copies of Annual Reports, and any other reports updating the progress of the CRADA research. However, the Parties must exchange updated Investigator’s Brochure, formulation and preclinical data, and toxicology findings, as they become available. In addition, all CRADA research meetings between the Collaborator and consultants, and the ICD scientific and clinical employees will be organized in advance through the office of ICD Principal Investigator, and the Collaborator President and Chief Operating Officer, and the Vice President, NIH Research Program Liaison of Genesis Biopharma, Inc.. All meetings, telephone and video conferences will be held at mutually agreeable times and dates to allow all relevant Collaborator and consultants, and ICD employees to participate.